Form 4: Ginkgo Bioworks Director Reshma Kewalramani Reports Stock Vesting

Sentiment:

SEC Form 4 Filing


Director Reshma Kewalramani reported the vesting of restricted stock units into Class A Common Stock of Ginkgo Bioworks Holdings, Inc.

Summary

  • On June 12, 2024, Reshma Kewalramani, a director of Ginkgo Bioworks Holdings, Inc., had restricted stock units (RSUs) vest into 105,263 shares of Class A Common Stock.
  • These RSUs were granted on June 16, 2023, and vested in full on June 12, 2024, contingent upon the director's continued service until the day before the next Annual Meeting of Shareholders.
  • Following the transaction, Kewalramani directly owns 186,002 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a routine transaction (vesting of stock). It doesn't inherently convey positive or negative sentiment.

Positives

  • The vesting of RSUs indicates continued service and commitment of the director to the company.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency regarding the holdings and transactions of company directors.

Stakeholder Impact

  • The vesting of RSUs has a minor dilutive effect on existing shareholders.

Key Dates

DateDescription
June 16, 2023Date the Restricted Stock Units (RSUs) were granted.
June 12, 2024Date the Restricted Stock Units (RSUs) vested and converted into Class A Common Stock.
June 14, 2024Date of the signature on the SEC Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.